Physician profile
Michael L Ross
NPI 1598945602
$1,203.83
in general payments reported to CMS, 2019-2025
23 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $196 · 2021: $126 · 2022: $94.82 · 2023: $178 · 2024: $244 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $186.29 | 2022-2025 | Farxiga, Breztri |
| Mannkind Corporation | $151.69 | 2019 | |
| Lilly USA, LLC | $149.30 | 2020-2023 | Emgality, Jardiance, Mounjaro |
| Novo Nordisk INC | $103.84 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Depuy Synthes Sales INC. | $68.01 | 2023-2025 | Peak, Orthovisc |
| Abbott Laboratories | $66.08 | 2024-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $56.27 | 2019-2021 | |
| Astellas Pharma US INC | $54.15 | 2023-2024 | Veozah |
| Pacira Therapeutics, INC. | $53.63 | 2020 | |
| Baxter Healthcare | $38.31 | 2022 | |
| Amgen INC. | $30.57 | 2019-2023 | Repatha |
| Abbvie INC. | $28.36 | 2021 | |
| Amarin Pharma, INC. | $26.10 | 2019 | |
| Covidien LP | $24.64 | 2019 | |
| Ibsa Pharma INC. | $21.06 | 2023 | Tirosint, Licart |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.90 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.47 | 2020 | |
| Gilead Sciences, INC. | $19.46 | 2021 | |
| Glaxosmithkline, LLC. | $19.36 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.60 | 2024 | Zilretta, Iovera |
| Sanofi Pasteur INC. | $18.11 | 2022 | |
| Allergan, INC. | $16.22 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.